Detroit Partner Daljit Doogal was quoted in an article from the online edition of Rubber News on June 26, 2013 titled, “Product Liability becoming shared responsibility for auto makers, suppliers.” The article discusses how the emphasis on shared responsibility has worked its way from the auto makers down to all three tiers of the supply chain as vehicle manufacturers increasingly require contributions from suppliers for potential product liability, warranty and recall claims. Mr. Doogal was quoted saying, “It’s a race to figuring out who, ultimately, is liable for the defective part. Most of the tier ones are solid players, but then you go further down the food chain to the tier twos and threes. They are definitely smaller companies that don’t have as much financial wherewithal that some of the tier ones have. “Mr. Doogal also said, “Before any deal goes through, most companies hire operational consultants to talk with the supplier’s employees and customers and look at the history of warranty and recall exposures. Companies that have higher incidents of warranty or product recall claims will depress the purchase price.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”